Skip to content

Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people

Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000003216
Enrollment
Unknown
Registered
2020-04-16
Start date
2020-04-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

The Fifth Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. At the time of signing the informed consent, male or female aged 18 to 65 years old; 2. Covid-19 convalescent patients, suspected patients, fever and other susceptible groups with respiratory symptoms of laryngeal discomfort; 3. The TCM syndrome differentiation of pharyngeal discomfort in the above population is as follows: dampness-heat accumulation lung syndrome/wind-heat syndrome/wind-heat invasion lung syndrome/phlegm-heat obstructing lung syndrome/lung-heat blazing syndrome/lung-stomach solid heat syndrome and other TCM syndromes; 4. Subject is informed and voluntarily signs an informed consent and agrees to participate in all visits as required by the study protocol.

Exclusion criteria

Exclusion criteria: 1. The researcher decides that it is not in the best interests of the subject to participate in this study, or there is any situation that the protocol cannot be safely followed; 2. Known allergic reaction or allergic constitution to gramanliyan oral liquid or its components; 3. Have participated in or are participating in other clinical researchers within the past 1 month; 4. Positive pregnancy test during pregnancy or breastfeeding or before medication; 5. Other circumstances considered inappropriate for the study.

Design outcomes

Primary

MeasureTime frame
New fever, cough, muscle soreness, headache, the time it takes for symptoms to disappear or to subside;Symptom scores;Occurrence of adverse events/reactions;Relief time and rate of symptoms of laryngeal discomfort, sore throat, dry and hot pharynx, and pharyngeal mucosal congestion;

Secondary

MeasureTime frame
Other symptoms such as fever, cough, muscle soreness, headache, etc.;Incidence of COVID - 19;Novel coronavirus positive rate;

Countries

China

Contacts

Public ContactHuang Mingxing

The Fifth Affiliated Hospital of Sun Yat-Sen University

huangmx5@mail.sysu.edu.cn+86 15989778816

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026